News
Clinical Trials Arena on MSN5d
First subject dosed in Cellarity’s trial of CLY-124 for sickle cell diseaseCellarity has dosed the first subject in a Phase I study of oral medication, CLY-124, to treat sickle cell disease (SCD).
Extreme pain, known as a pain crisis, is one of the hallmark symptoms of SCD. With frequent hospitalizations, chronic pain ...
The Punch on MSN12d
Sickle Cell and early diagnosis: Recognising signs of SCD in infantsSickle cell disease is one of the most common inherited blood disorders worldwide, with a particularly heavy burden in sub-Saharan Africa. Every year, hundreds of thousands of infants are born with ...
At Miami-Dade’s public hospital system Jackson Health, new advancements in genetic research recently helped doctors modify a ...
The World Health Organization has released its first-ever global guideline on the management of sickle cell disease during ...
Dr Rossby Awadzi, a GP trainee and Sickle Cell Clinical Fellow at NHS England with a passion for red cell medicine, explains ...
BEAM-101, a treatment for sickle cell disease, showed sustained efficacy and safety over one year in the BEACON Phase 1/2 ...
Most people with SCD seem to meet or exceed current level of physical activity recommendations for the general population, a ...
Dr. Omar H. Llaguna, specialist in surgical oncology, programs a HistoSonics medical device for targeting a medium that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback